Please try another search
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Daniel D. Burgess | 59 | 2014 | Independent Chairman of the Board |
David L. Gollaher | 71 | 2018 | Independent Director |
Timothy R. Franson | 69 | 2015 | Independent Director |
Theodore R. Schroeder | 66 | 2014 | Independent Director |
Chrysa Mineo | 56 | 2018 | Independent Director |
Jeffrey L. Stein | 66 | 2014 | President, CEO & Executive Director |
Perry D. Nisen | 67 | 2022 | Member of the Scientific Advisory Board |
Bonnie L. Bassler | 61 | 2021 | Independent Director |
Carin Canale-Theakston | 48 | 2021 | Independent Director |
Stephen P. Schoenberger | - | 2023 | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review